Observation on the effect of abnormal serum glycoprotein expression and cellular immune function on the prognosis of lung cancer

Objective To observe the effect of abnormal serum glycoprotein (TAP) expression and cellular immune function on the prognosis of lung cancer patients. Methods Clinical data of 49 patients with lung cancer admitted to the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2016 to May 2017 were selected and divided into observation groups (radical surgery plus postoperative adjuvant chemotherapy, n=28) and control group (chemotherapy, n=21) according to treatment methods. Serum TAP expression and cellular immune function were measured before treatment and at the 1st and 3rd months after treatment, and Karnofsky (KPS) functional status scores were also measured. Results The positive rates of TAP expression before treatment in the two groups were not statistically significant (P>0.05). The positive rate of TAP expression at the 1st and 3rd months after treatment in the observation group was significantly lower, and the difference was statistically significant (P 0.05). At the 1st and 3rd months after treatment, the positive rate of TAP expression in the observation group was significantly lower than that in the control group, and the difference was statistically significant (P 0.05), but at the 3rd month the ratio lowered significantly (P<0.05). At the 1st and 3rd months after treatment, the ratio of CD4+ /CD8+ in the observation group was significantly higher than that in the control group, and the difference was statistically significant (P<0.01). The KPS score showed that at the 3rd month after treatment the effective rate was 37.1% in the observation group, and 38.1% in the control group. The effective rate in the observation group was significantly better than that in the control group, the difference was statistically significant (P=0.007). Conclusions Serum TAP and cellular immune function can be used as indicators to evaluate prognosis and recurrence of lung cancer and have clinical application value. Key words: Lung cancer; Abnormal glycoprotein; Cellular immune function; Prognosis